Intensivmedizin und Notfallmedizin

, Volume 47, Issue 8, pp 576–581 | Cite as

Leberunterstützungstherapien 2010

Mehr Fragen als Antworten
Leitthema

Zusammenfassung

Im Frühjahr 2010 wurden erneut 2 Studien präsentiert, die keine Verbesserung der Sterblichkeit der Patienten mit akut-auf-chronischem Leberversagen zeigten, obwohl sie mit einem Leberunterstützungssystem behandelt wurden. Die Autoren dieses Beitrags schlagen als Ursache für die negativen Studienergebnisse eine unzureichende Entgiftungsfunktion der Verfahren vor. Am Beispiel der Marker Ammoniak und Bilirubin wird erläutert, welche Entgiftungsziele für eine erfolgreiche Therapie anzusetzen sind. Zusätzlich werden weitere notwendige Funktionen eines Leberunterstützungssystems definiert wie Elektrolytausgleich und Kontrolle des Wasser- und Säure-Basen-Haushaltes. Auf die besondere Bedeutung der Vermeidung von Nebenwirkungen wird hingewiesen, da hierdurch die positiven Ergebnisse der Therapie zunichte gemacht werden können. Weitere offene Fragen betreffen die Auswahl der Patienten, des Therapiebeginns oder die Frage einer intermittierenden vs. einer kontinuierlichen Therapie. In diesem Kontext wird auch der derzeitige Stellenwert bioartifizieller Leberunterstützungssysteme besprochen.

Schlüsselwörter

Leberunterstützungssystem Leberzirrhose Bilirubin Multiorganversagen Klinische Studien 

Liver support systems 2010

More questions than answers

Abstract

In the spring of 2010, two clinical studies that showed no improvement in the mortality of patients suffering from acute-on-chronic liver failure by treatment with liver support systems were presented. The authors of the present article suggest that the reason for the negative results is the inadequate detoxification capacity of the procedures. With the example of the surrogate markers ammonia and bilirubin, the detoxification targets for successful therapy are illustrated. In addition, other necessary functions of liver support systems, including acid–base balance, electrolyte balance, and control of water balance, are defined. The importance of avoiding side effects is particularly stressed, since the positive effects of therapy can be overshadowed. Other open questions deal with the selection of patients, the start of therapy or the issue of intermittent versus continuous therapy. In this context, the current status of bioartificial liver support systems is discussed.

Keywords

Artificial liver Liver cirrhosis Bilirubin Multiple organ failure Clinical trial 

Literatur

  1. 1.
    Ahya SN, Jose Soler M, Levitsky J et al (2006) Acid-base and potassium disorders in liver disease. Semin Nephrol 26:466–470CrossRefPubMedGoogle Scholar
  2. 2.
    Al-Chalabi A, Kreymann B, Langgartner J et al (2009) Möglichkeiten und Zukunftsperspektiven der Leberersatztherapie. Intensivmed Notfallmed 46:347–354CrossRefGoogle Scholar
  3. 3.
    Al-Chalabi A, Matevossian E, Preissel AK et al (2010) 818 survival improvement in pigs with liver failure and superimposed sepsis by a new liver support system (Hepa Wash®). J Hepatol 52:S319Google Scholar
  4. 4.
    Al-Chalabi A, Matevossian E, Preissel AK et al (2010) 819 improvement of survival in a swine model of acute liver failure by a new liver support system (Hepa Wash®). J Hepatol 52:S319–S320Google Scholar
  5. 5.
    Arteh J, Narra S, Nair S (2010) Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci 55:2624–2628CrossRefPubMedGoogle Scholar
  6. 6.
    Bañnares R, Nevens F, Larsen FS et al (2010) 1184 Extracorporeal liver support with the Molecular Adsorbent Recirculating System (MARS) in patients with acute-on-chronic liver failure (AOCLF). The RELIEF trial. J Hepatol 52:S459–S460CrossRefGoogle Scholar
  7. 7.
    Bellomo R, Cass A, Cole L et al (2009) Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 361:1627–1638CrossRefPubMedGoogle Scholar
  8. 8.
    Berk PD, Howe RB, Bloomer JR et al (1969) Studies of bilirubin kinetics in normal adults. J Clin Invest 48:2176–2190CrossRefPubMedGoogle Scholar
  9. 9.
    Carpentier B, Gautier A, Legallais C (2009) Artificial and bioartificial liver devices: present and future. Gut 58:1690–1702CrossRefPubMedGoogle Scholar
  10. 10.
    Charalabopoulos K, Peschos D, Zoganas L et al (2007) Alterations in arterial blood parameters in patients with liver cirrhosis and ascites. Int J Med Sci 4:94–97PubMedGoogle Scholar
  11. 11.
    Cholongitas E, Senzolo M, Patch D et al (2006) Risk factors, sequential organ failure assessment and model for end-stage liver disease scores for predicting short term mortality in cirrhotic patients admitted to intensive care unit. Aliment Pharmacol Ther 23:883–893CrossRefPubMedGoogle Scholar
  12. 12.
    Cordoba J, Blei AT, Mujais S (1996) Determinants of ammonia clearance by hemodialysis. Artif Organs 20:800–803CrossRefPubMedGoogle Scholar
  13. 13.
    Davenport A (2009) Can advances in hemodialysis machine technology prevent intradialytic hypotension? Semin Dial 22:231–236CrossRefPubMedGoogle Scholar
  14. 14.
    Dellinger RP, Levy MM, Carlet JM et al (2008) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36:296–327CrossRefPubMedGoogle Scholar
  15. 15.
    Fernandez-Mondejar E, Guerrero-Lopez F, Colmenero M (2007) How important is the measurement of extravascular lung water? Curr Opin Crit Care 13:79–83CrossRefPubMedGoogle Scholar
  16. 16.
    Funk GC, Doberer D, Kneidinger N et al (2007) Acid-base disturbances in critically ill patients with cirrhosis. Liver Int 27:901–909CrossRefPubMedGoogle Scholar
  17. 17.
    Geerse DA, Bindels AJ, Kuiper MA et al (2010) Treatment of hypophosphatemia in the intensive care unit: a review. Crit Care 14:R147CrossRefPubMedGoogle Scholar
  18. 18.
    Hassanein TI, Tofteng F, Brown RS Jr et al (2007) Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 46:1853–1862CrossRefPubMedGoogle Scholar
  19. 19.
    Haussinger D (2004) Neural control of hepatic osmolytes and parenchymal cell hydration. Anat Rec 280:893–900CrossRefGoogle Scholar
  20. 20.
    Haussinger D (2008) Osmosensing and osmosignaling in the liver. Wien Med Wochenschr 158:549–552CrossRefPubMedGoogle Scholar
  21. 21.
    Iwata H, Ueda Y (2004) Pharmacokinetic considerations in development of a bioartificial liver. Clin Pharmacokinet 43:211–225CrossRefPubMedGoogle Scholar
  22. 22.
    Jenq CC, Tsai MH, Tian YC et al (2010) Serum sodium predicts prognosis in critically ill cirrhotic patients. J Clin Gastroenterol 44:220–226CrossRefPubMedGoogle Scholar
  23. 23.
    Jepsen P, Ott P, Andersen PK et al (2010) Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology 51:1675–1682CrossRefPubMedGoogle Scholar
  24. 24.
    Jung A, Krisper P, Haditsch B et al (2006) Bilirubin kinetic modeling for quantification of extracorporeal liver support. Blood Purif 24:413–422CrossRefPubMedGoogle Scholar
  25. 25.
    Liu JP, Gluud LL, Als-Nielsen B et al (2004) Artificial and bioartificial support systems for liver failure. Cochrane Database Syst Rev CD003628Google Scholar
  26. 26.
    Palevsky PM, Zhang JH, O’connor TZ et al (2008) Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 359:7–20CrossRefPubMedGoogle Scholar
  27. 27.
    Rifai K, Kribben A, Gerken G et al (2010) 6 Extracorporeal liver support by fractionated plasma separation and adsorption (Prometheus) in patients with acute-on-chronic liver failure (HELIOS Study): a prospective randomized controlled multicenter study. J Hepatol 52:S3CrossRefGoogle Scholar
  28. 28.
    Roberts SE, Goldacre MJ, Yeates D (2005) Trends in mortality after hospital admission for liver cirrhosis in an English population from 1968 to 1999. Gut 54:1615–1621CrossRefPubMedGoogle Scholar
  29. 29.
    Stravitz RT, Larsen FS (2009) Therapeutic hypothermia for acute liver failure. Crit Care Med 37:S258–S264CrossRefPubMedGoogle Scholar
  30. 30.
    Umgelter A, Reindl W, Wagner KS et al (2008) Effects of plasma expansion with albumin and paracentesis on haemodynamics and kidney function in critically ill cirrhotic patients with tense ascites and hepatorenal syndrome: a prospective uncontrolled trial. Crit Care 12:R4CrossRefPubMedGoogle Scholar
  31. 31.
    Vinsonneau C, Camus C, Combes A et al (2006) Continuous venovenous haemodiafiltration versus intermittent haemodialysis for acute renal failure in patients with multiple-organ dysfunction syndrome: a multicentre randomised trial. Lancet 368:379–385CrossRefPubMedGoogle Scholar
  32. 32.
    Yunos NM, Bellomo R, Story D et al (2010) Bench-to-bedside review: chloride in critical illness. Crit Care 14:226CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Hepa Wash GmbHMünchenDeutschland
  2. 2.Klinik und Poliklinik für Innere Medizin IIKlinikum rechts der Isar, Technische Universität MünchenMünchenDeutschland

Personalised recommendations